Orchard Therapeutics Stock Price - ORTX

-0.04 (-0.31%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Orchard Therapeutics PLC ORTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
2.22 20.81% 12.89 10.16 13.09 10.30 10.67 17:23:16
Bid Price Ask Price Spread Spread % News
12.78 12.85 0.07 0.54% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,132 1,871,493 $ 11.81 $ 22,102,684 277,846 9.78 - 21.64
Last Trade Time Type Quantity Stock Price Currency
17:38:07 50 $ 12.85 USD

Orchard Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.24B 96.52M $ -230.50M -25.17 - 96.52M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Orchard Therapeutics News

Loading Messages....

Latest ORTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ORTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week12.2713.0910.1611.36524,2160.625.05%
1 Month12.9313.2910.1612.05307,583-0.04-0.31%
3 Months11.6315.9310.1613.24323,4441.2610.83%
6 Months13.2817.489.7813.02267,986-0.39-2.94%
1 Year16.7621.649.7814.07221,876-3.87-23.09%
3 Years17.0021.648.6514.14195,444-4.11-24.18%
5 Years17.0021.648.6514.14195,444-4.11-24.18%

Orchard Therapeutics Description

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Your Recent History
Orchard Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.